logo
userIcon_c meanIcon_c searchIcon_c
logo userIcon_w meanIcon_c searchIcon_c

CONFERENCE UPDATE: EADV 2022

Baricitinib as a potential therapeutic option for moderate-to-severe AD children

DERMATOLOGY
02 Dec 2022
share
bookmark
copy

Login
Get access to our exclusive articles.
Related Articles

Dupilumab as the first and only drug gains FDA approval for treating EoE

Dupilumab, a monoclonal antibody previously indicated for the treatment of atopic dermatitis and asthma, has been recently approved by the United States (US) Food and Drug Administration (FDA) for treating eosinophilic esophagitis (EoE), a chronic, inflammatory disease in which the build-up of a typ

DERMATOLOGY RESPIROLOGY
25 Jul 2022

Baricitinib yields favorable outcomes in JIA: the phase 3 JUVE-BASIS trial

RHEUMATOLOGY
19 Jul 2022
footerLeft
CARDIOLOGY
DERMATOLOGY
DIABETES & ENDOCRINOLOGY
GASTROENTEROLOGY & HEPATOLOGY
HEMATOLOGY
INFECTIOUS DISEASE
NEPHROLOGY
NEUROLOGY
OBSTETRICS & GYNECOLOGY
ONCOLOGY
OPHTHALMOLOGY
PEDIATRICS
PSYCHIATRY
RESPIROLOGY
RHEUMATOLOGY
UROLOGY
ABOUT US
BE IN TOUCH
TERMS OF USE
PRIVACY POLICY
footerRight
Copyright ©2023 Omnihealth Practice. All rights reserved.
A healthcare professionals channel of Omnihealth Group